KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $18.5 million.

  • Biomarin Pharmaceutical's Depreciation & Amortization (CF) fell 273.07% to $18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year decrease of 1700.84%. This contributed to the annual value of $96.4 million for FY2024, which is 762.55% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Depreciation & Amortization (CF) of $18.5 million as of Q3 2025, which was down 273.07% from $18.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Depreciation & Amortization (CF) ranged from a high of $28.0 million in Q1 2021 and a low of $18.5 million during Q3 2025
  • In the last 5 years, Biomarin Pharmaceutical's Depreciation & Amortization (CF) had a median value of $25.7 million in 2023 and averaged $24.7 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Depreciation & Amortization (CF) soared by 940.01% in 2023, and later tumbled by 2985.3% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Depreciation & Amortization (CF) stood at $26.0 million in 2021, then fell by 5.51% to $24.6 million in 2022, then grew by 9.4% to $26.9 million in 2023, then decreased by 12.11% to $23.6 million in 2024, then fell by 21.69% to $18.5 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $18.5 million for Q3 2025, versus $18.6 million for Q2 2025 and $22.1 million for Q1 2025.